Olmesartan/Amlodipin/Hydrochlorthiazid Krka (Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide)

Olmesartan medoxil, the active ingredient in Olmesartan/Amlodipin/Hydrochlorthiazid Krka, is a angiotensin II receptor blocker presented as a tablet for oral use. It treats hypertension, often in combination with other antihypertensive agents, and is suitable for adult patients. GNH USA supplies Olmesartan/Amlodipin/Hydrochlorthiazid Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmesartan/Amlodipin/Hydrochlorthiazid Krka is manufactured by Krka and marketed as a fixed‑dose combination therapy for high blood pressure.

Olmesartan/Amlodipin/Hydrochlorthiazid Krka is used in the management of hypertension, targeting the renin‑angiotensin system and vascular smooth‑muscle tone. - Hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk. - Hypertensive urgency: provides rapid, controlled reduction of elevated blood pressure when immediate treatment is required. - Resistant hypertension: adds complementary mechanisms to achieve target blood pressure when monotherapy is insufficient.

Side effects may occur with any antihypertensive regimen and vary in frequency.

Common Side Effects: - Dizziness or light‑headedness, especially after the first doses. - Peripheral edema, often noticeable in the ankles. - Headache, typically mild and transient. - Flushing or warmth sensation. - Fatigue or general tiredness. - Increased urination due to the diuretic component.

Serious or Rare Side Effects: - Severe hypotension leading to fainting. - Acute kidney injury manifested by sudden rise in creatinine. - Electrolyte disturbances such as low potassium or sodium. - Angio‑edema affecting the face, lips or airway. - Liver enzyme elevations indicating hepatic stress. - Allergic reactions ranging from rash to anaphylaxis.

When prescribing Olmesartan/Amlodipin/Hydrochlorthiazid Krka, clinicians should consider several safety aspects. - Monitor blood pressure: ensure adequate control without excessive lowering. - Assess renal function: check creatinine and electrolytes before and during therapy. - Evaluate electrolytes: watch for hyponatremia or hypokalemia, especially with the thiazide component. - Review cardiac status: caution in patients with severe aortic stenosis or heart failure. - Pregnancy and lactation: avoid use; teratogenic risk is recognized for ARBs. - Store at ambient temperature: keep below 25°C, protect from moisture and light, retain in original packaging.

Olmesartan/Amlodipin/Hydrochlorthiazid Krka can interact with several other medicines; awareness helps prevent adverse events.

Major Interactions (Avoid): - Concomitant use with aliskiren in patients with diabetes or renal impairment. - Potassium‑rich supplements or potassium‑sparing diuretics, which may cause hyper‑kalemia. - Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin) that increase amlodipine levels.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs) that may blunt antihypertensive effect. - Lithium, as thiazides reduce renal clearance and raise lithium concentrations. - Antidiabetic agents, since blood‑pressure reduction can enhance glucose‑lowering effects. - Alcohol, which may increase dizziness and hypotensive response. - Other antihypertensives, requiring dose adjustments to avoid excessive blood‑pressure fall.